Efficacy and safety of carfilzomib weekly 20/56mg/m² plus lenalidomide and dexamethasone regimen in patients with early relapsed refractory multiple myeloma (RRMM)
Latest Information Update: 03 Sep 2019
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Results of long-term exposure data on KRd weekly given until progression presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology